Evolus, Inc.
Every calculator, already run for EOLS
Open the full toolkit →You have the numbers on EOLS. Get the argument.
A written report on which of these readings actually decide the outcome for Evolus, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering EOLSAnalyst Price Target Disagreement for Evolus, Inc.
Wall Street's bull case implies +154% from the current price; the bear case implies +53%. A 102% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for EOLS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS — frequently asked
Is EOLS a buy right now?
Wall Street's consensus rating on Evolus, Inc. is Strong Buy across 6 analysts, with a mean price target of $15.00 (+91% vs. the current $7.86). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is EOLS's next earnings date?
Evolus, Inc. is next scheduled to report earnings around Nov 4, 2026. A full EOLS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Evolus, Inc.?
Analysts covering Evolus, Inc. (EOLS) range from a bear-case target of $12.00 to a bull-case high of $20.00, with a mean consensus target of $15.00 across 5 analysts. The spread of $8.00 (102% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Evolus, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Evolus, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EOLS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Evolus, Inc., in minutes. 3 free reports included with every account — no credit card required.